What is Vildagliptin?

Vildagliptin is a substance used to treat diabetes mellitus type 2, more often known as type 2 diabetes. It is used for patients who cannot control blood sugar levels or blood glucose, with other antidiabetic drugs. Natišenávodní pharmaceutical company based in the Swiss Novartis International AG sells a drug under the trade name Galvus. Sometimes it is called diabetes for adults to distinguish it from diabetes 1. Type or juvenile diabetes. In any case, the presence of diabetes indicates a lack of insulin hormone, which leads to an increase in blood sugar. Vildagliptin is introduced to an increase in the amount of two hormones named glucagon peptide-1 (GLP-1) and insulinotropic peptide dependent on glucose (GIP), which contributes to control of body glucose. Anti-diabetes drug does this inhibited by dipeptidyl peptidase 4 (DPP4), protein that inactivates GLP-1 and GIP.

Vildagliptin can also be combined with other antidiabetic drugs. Perhaps the most common combinationIt is EUCREAS, another trade name from Novaris, which is a combination of vildagliptin and metformin. In fact, it is the first line for the treatment of diabetes 2. Type A is one of the most used antidiabetic drugs in the world.

Another popular candidate for combination, sulphonylurea, works by increasing insulin from beta cells of pancreas. Other anti-diabetic drugs that are commonly associated with vildagliptin include rosiglitazone, Avandia brand; and pioglitazone, brand Actos. Both belong to the class of five -member heterocyclic remedies to strengthen the ring called Thiazolidinedions.

side effects of vildagliptin include constipation, dizziness, fatigue, headaches, nausea, swelling of the legs and ankles, tremor, weakness and weight. Most of these side effects are caused when the drug is combined with metformin, sulphonylreau or glitazone. Doctors can retain vildagliptin if the patient is older 75Flight, has mild heart failure or uses inhibitors of enzyme converting angiotensin (ACE), which are drugs used to treat the above state, as well as hypertension.

26. September 2007 was allowed by the European Agency for Medicine (EMA) Vildagliptin. The European Commission, the executive body of the European Union (EU), then approved the medicine on 1 February 2008 for the purpose of introducing in its Member States. Twenty -four days later the same body approved Eucreas.

Since then, Vildagliptin has launched in 37 countries and was approved in 70 countries. However, Novaris did not submit the drug to the US food and drug administration (FDA). This stopped the approval of a drug in the US because the FDA demanded other clinical data with regard to skin forest with he and the kidneys that appeared in animal studies.